A randomized, double‐blind, placebo‐controlled, phase 3 study of tivantinib in Japanese patients with MET‐high hepatocellular carcinoma

A previous randomized phase 2 study of hepatocellular carcinoma revealed that the c‐Met inhibitor tivantinib as second‐line treatment significantly prolonged progression‐free survival in a subpopulation whose tumor samples highly expressed c‐Met (MET‐high). Accordingly, this phase 3 study was conduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Masatoshi, Morimoto, Manabu, Moriguchi, Michihisa, Izumi, Namiki, Takayama, Tetsuji, Yoshiji, Hitoshi, Hino, Keisuke, Oikawa, Takayoshi, Chiba, Tetsuhiro, Motomura, Kenta, Kato, Junko, Yasuchika, Kentaro, Ido, Akio, Sato, Takashi, Nakashima, Daisuke, Ueshima, Kazuomi, Ikeda, Masafumi, Okusaka, Takuji, Tamura, Kazuo, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541009/
https://www.ncbi.nlm.nih.gov/pubmed/32716114
http://dx.doi.org/10.1111/cas.14582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541009/
https://www.ncbi.nlm.nih.gov/pubmed/32716114
http://dx.doi.org/10.1111/cas.14582

Ejemplares similares